Download Free Medical OSTEOPOROSIS An update PowerPoint Presentation

OSTEOPOROSIS An update PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Orthopaedics, which is titled "OSTEOPOROSIS An update", to know about OSTEOPOROSIS.

Tags : Orthopaedics, OSTEOPOROSIS

Published on : Aug 18, 2021 | Views : 1286 | Downloads : 4

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

OSTEOPOROSIS An update May 2012
Slide 2-

Df: A progressive systemic skeletal disorder characterised by a low bone mass and micro-architectural deterioration of bone. T score of < -2.5 when measuring bone mineral density on DEXA scan (Dual –energy x-ray absorptiometry) Osteopenia: T score -1 to -2.5. Osteoporosis
Slide 3-

Z score- bone strength compared to other people in your own age T score- compares bone density to that of a 25 year old. Measures bone mineral density using central hip and/or spine DEXA scanning and is expressed in the number of standard deviations below peak bone mineral density. DEXA Scans
Slide 4-

ppt slide no 4 content not found
Slide 5-

70,000 hip and 120,000 spine and 50,000 wrist # a yr due to osteoporosis . 1 > 1/3rd of women sustain a # relating to osteoporosis. 2 Costing NHS > 940 M a yr. 2 Why is it important?
Slide 6-

Bone remodelling predominates 15-17 yrs (once longitudinal growth ceases) Consists of: bone dissolution/resorption by osteoclasts + bone formation by osteoblasts Adults, remodelling cycle is balanced so resorption = bone formation (90-130 days) Quick revision
Slide 7-

However remodelling can become imbalanced so result in significant bone loss Age-related bone loss starts in 40’s/50’s as a result of: ↑ed bone breakdown by osteoclasts ↓ed bone formation by osteblasts
Slide 8-

Hormonal. Late menarche, early menopause, long hx of oligomenorrhoea. During menopause oestrogen deprivation ↑ed bone resorption, so→ bone loss. Smoking Excessive alcohol intake Risk Factors
Slide 9-

Lack of weight bearing exercise Vitamin D deficiency Glucocorticoid exposure. ↓ Ca absorption, ↑ bone resorption, ↓ bone formation, thus → bone loss.
Slide 10-

< 75 yrs DEXA scan 3 Bloods: FBC, ESR, TSH, U+E’s, bone and LFTs. Consider checking serum paraproteins /urinary Bence Jones proteins to exclude other causes for # such as: Investigations
Slide 11-

Other possible causes of #: Malignancy, Osteomalacia, Hyperparathyroidism 4
Slide 12-

If ≥ 75 yrs + DEXA clinically inappropriate clincial assessment is sufficient for diagnosis. 3
Slide 13-

Management Non-pharmacological Pharmacological
Slide 14-

Diet. 1000 mg Calcium daily intake for postmenopausal women →24 % reduction in hip #.5 1000 mg equivalent to 1 pint milk/50 g cheese/50 g sardines/1 pot of yogurt. Avoid caffeinated products. Evidence inconclusive. Regular exercise. Weight bearing exercise > 30 mins/day ↓# rate. 4 Non-pharmacological
Slide 15-

Stop smoking. Pre-menopause leads to 25 % ↓# rate postmenopausal 4 ↓alcohol consumption to < 21 units/wk male, <14 units/wk women 4
Slide 16-

1. osteoporosis, no # 2. osteoporosis, already sustained # Pharmaocological(NICE guidance)3
Slide 17-

1st line Alendronate 2nd line Risedronate and Etidronate 3rd line Strontium Ranelate 4th line Denosumab 1o prevention of osteoporotic # in PM women
Slide 18-

1st line alendronate 2nd line risedronate/etidronate 3rd line strontium ranelate/raloxifene 4th line teriparatide 2o Prevention of # in PM women who have sustained osteoporotic #
Slide 19-

If there are contraindications, intolerances or side effects then the next line of treatment should be tried. As an adjunct to treatment calcium and vitamin D supplementation should be considered in patients with a diagnosis of osteoporosis.
Slide 20-

Alendronic acid/risedronate/etidronate MOA: adsorbed onto hydroxyapatite crystals in bone, slowing both their rate of growth + dissolution so ↓ the rate of bone turn over. 6 Poorly absorbed.1-5 % of oral dose actually absorbed. 5 Bisphosphonates
Slide 21-

Special instructions: To be swallowed whole, with water while sitting or standing on an empty stomach 30 mins before breakfast. Pt should then stand or sit upraight for at least 30 mins after taking the tablet. Side effects: oesophageal reactions- oesophagitis/ulcers/stricture/erosions.
Slide 22-

Alendronic Acid Dose:6 Men 10 mg daily Women 70 mg OW if postmenopausal, 10 mg daily if corticosteroid induced osteoporosis not on HRT.
Slide 23-

MOA: stimulates bone formation + reduces bone resorption. 6 Special instructions: Avoid food 2 hrs before and after taking in particular calcium- containing products Side effects: severe allergic reactions such as drug rash with eosinophilia and systemic symptoms (DRESS). Signs: rash/fever/swollen glands/ ↑ WCC Dose: 2 g OD. Strontium Ranelate
Slide 24-

MOA: SERM, beneficial effects on bone, but no effect on breast or endometrium. CI: past VTE, endometrial carcinoma Dose: 60 mg OD Raloxifene
Slide 25-

MOA: recombinant fragment of parathyroid hormone. Increasing availability of Calcium. Special instructions- only initiated by specialists experienced in the treatment of osteoporosis. Dose: 20 mcg OD s/c Teriparatide
Slide 26-

Tx option for the 10 prevention of osteoporotic # if the following apply: Postmenopausal women at ↑ ed risk of # Unable to comply with special instructions for administering alendronate/risedronate/etidronate Intolerances or CI to the above Can be used in pts who have a combination of T-score + age and no. of independent clinical risk factors for # (see nxt box) Denosumab 7 New NICE guidance
Slide 27-

Independent risk factors: 1. Parental history of hip # 2. Alcohol intake ≥ 4 units per day 3. RA
Slide 28-

Which of the following is considered a second line option for the primary prevention of # in postmenopausal women? Select ONE option only. Raloxifene Adcal D3 + Risedronate Teriparatide Alendronic acid AKT Question
Slide 29-

B is the correct answer. A+C are used in secondary prevention D is first line for primary prevention Answer
Slide 30-

Osteoporosis. An Information booklet. www.arc.org.uk Updated May 2007. Royal College of Physicians. Clinical Guidelines for the prevention and treatment of osteoporosis. www.rcplondon.ac.uk/ NICE guidance Oct 2008 http://www.nice.org.uk/nicemedia/live/11746/42486/42486.pdf Oxford Handbook of General Practice. P568-569 References
Slide 31-

SIGN (Scottish intercollegiate guidelines network) guidelines for osteoporosis. http://www.sign.ac.uk/guidelines updated 2004. BNF Chapter 6.6.2 p463. Bisphospahtes and other drugs affecting bone metabolism. Denosumab for the prevention of osteoporotic fractures in fractures in postmenopausal women Nice Guidance, Oct 2010. http://www.nice.org.uk/nicemedia/live/13251/51329/51329.pdf